Asthma drug tested to slow ovarian cancer return
NCT ID NCT04339140
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This study tested whether zafirlukast, an asthma drug, can control ovarian cancer that is only detected by rising CA-125 levels in the blood. Five women with this type of relapse took the drug to see if it could lower their CA-125 levels. The goal was to delay or prevent further tumor growth without using chemotherapy right away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.